NASDAQ · Biotechnology · USD

Cognition Therapeutics, Inc. (CGTX) Stock Analysis

Cognition Therapeutics, Inc. (CGTX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

CGTX

$1.03

−$0.02 (−1.90%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare CGTX with… →

CGTX Key Statistics

As of Sep 4, 2026

Trading

Open: $1.05
Previous Close: $1.05
Day's Range: 1.01–1.05
52-Week Range: 0.55–2.67
Volume: 377.50K
Beta: 1.79

Valuation

Market Cap: $97.95M
P/E Ratio: unprofitable
EPS (ttm): −0.17

Financials (FY)

Revenue (FY): $0.00
Net Income (FY): −$23.49M
Profit margin: 0.00%
Shares Outstanding: 95.09M
1-Year Return: −60.23%

Dividend and dates

Avg Volume: 1.19M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

CGTX Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

−50.51%−66.77%−11.90%−62.11%+92.58%−23.70%

2021*20222023202420252026*

Year	Return
2026 (partial year)	−23.70%
2025	+92.58%
2024	−62.11%
2023	−11.90%
2022	−66.77%
2021 (partial year)	−50.51%

As of September 4, 2026.

CGTX Revenue and Earnings by Fiscal Year

FY ends December

RevenueNet income

2022202320242025

Fiscal year	Revenue	Net income	Net margin
2025	$0.00	−$23.49M	—
2024	$0.00	−$33.97M	—
2023	$0.00	−$25.79M	—
2022	$0.00	−$21.40M	—

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	$0.00	—	−$24.39M	−$23.49M	—
2024	$0.00	—	−$34.42M	−$33.97M	—
2023	$0.00	—	−$25.92M	−$25.79M	—
2022	$0.00	—	−$21.33M	−$21.40M	—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

CGTX Valuation vs Biotechnology Median

Median of 656 stocks

Metric	CGTX	Biotechnology median	vs median
Profit margin	0.00%	0.00%	0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

Cognition Therapeutics, Inc. (CGTX) is capitalised at $97.95M on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 14 employees.

The most recent close on file for CGTX is $1.03, dated September 4, 2026. That is −$0.02 (−1.90%) against the previous close. Over the past 52 weeks the price has ranged from $0.55 to $2.67. The latest close sits 87.27% above that 52-week low.

Financial Health

In fiscal 2025, Cognition Therapeutics, Inc. reported revenue of $0.00. The same year closed with a net loss of $23.49M. Profit margin runs at 0%. Earnings per share on a trailing basis come to −0.17.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

Beta against the wider market is reported at 1.79. Annualized volatility over the trailing 4 years is 116.64%. The trailing one-year price return is −60.23%. Measured over 3 years, that is −12.92% a year compounded.

Growth & Income

The record shows no dividend for CGTX.

2026 is still running; the price is −23.70% year to date. Across the complete calendar years on file, 2025 returned +92.58% and 2022 returned −66.77%. Of the 4 complete calendar years on file, 1 finished higher.

Peer Comparison

Cognition Therapeutics, Inc. (CGTX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
Cognition Therapeutics, Inc.	CGTX	$97.95M	—
Vertex Pharmaceuticals Incorporated	VRTX	$138.42B	32.5
Regeneron Pharmaceuticals, Inc.	REGN	$85.22B	20.5
argenx SE	ARGX	$64.25B	40.1

The Biotechnology industry average P/E ratio is 12.6x. Cognition Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

ARGX

argenx SE

$64.25B

MRNA

Moderna, Inc.

$58.11B

RVMD

Revolution Medicines, Inc.

$45.01B

ONC

BeOne Medicines AG

$40.53B

View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

JNJ

Johnson & Johnson

$663.28B

ABBV

AbbVie Inc.

$453.19B

MRK

Merck & Co., Inc.

$370.89B

UNH

UnitedHealth Group Incorporated

$356.47B

View all Healthcare stocks →

About Cognition Therapeutics, Inc.

Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is zervimesine, an orally delivered small molecule to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, which is in Phase 2 clinical studies for the treatment of Alzheimer's disease and Mild Cognitive Impairment, as well as geographic atrophy secondary to dry age-related macular degeneration and dementia with Lewy bodies. Cognition Therapeutics, Inc. was incorporated in 2007 and is based in Purchase, New York.

Visit website →